Impact du dépistage systématique des phéochromocytomes chez les patients atteints de neurofibromatose de type 1
A. Agius(Hôpital Louis Pradel), Mona Amini‐Adlé(Centre Léon Bérard), L. Képénékian(Hospices Civils de Lyon), Marco Basset(University of Pavia), Sylvie Chabaud(Centre de Recherche en Cancérologie de Lyon), P. Combemale(Centre Léon Bérard), Sophie Darnis(Centre Léon Bérard), J. Abeillon(Centre National de la Recherche Scientifique), Hélène Lasolle(Hospices Civils de Lyon), F. Borson-Chazot(Hôpital Louis Pradel), J.C. Lifante(Hospices Civils de Lyon), G. Raverot(Hospices Civils de Lyon)
Cited by 0
Related Papers
Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial
|The Lancet Oncology|2015|432
Long‐term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42‐month analysis of the phase II randomized, double‐blind BOLT study
|British Journal of Dermatology|2019|197
Translocation, t(17;22)(q22;q13), in dermatofibrosarcoma protuberans: a new tumor-associated chromosome rearrangement
|Cytogenetics and Cell Genetics|2008|194
Long‐term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30‐month analysis of the randomized phase 2 BOLT study
|Journal of the European Academy of Dermatology and Venereology|2017|192
Neurofibromatosis 1 French national guidelines based on an extensive literature review since 1966
|Orphanet Journal of Rare Diseases|2020|188